Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Crohn Disease

ClinicalTrials.gov lists 1,937 trials for Crohn Disease or a narrower condition beneath it. Takeda has the most among industry and government lead sponsors, with 68.

MeSH D003424 Digestive System Diseases C06 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 119 Phase 1/2 Phase 1/2 66 Phase 2 Phase 2 220 Phase 2/3 Phase 2/3 27 Phase 3 Phase 3 211 Phase 4 Phase 4 149 Not applicable Not applicable 487 Observational Observational 652 Phase 1 Phase 1 119 Phase 1/2 Phase 1/2 66 Phase 2 Phase 2 220 Phase 2/3 Phase 2/3 27 Phase 3 Phase 3 211 Phase 4 Phase 4 149 Not applicable Not applicable 487 Observational Observational 652

Trials per phase (log scale)

1 more section with rows

1,937 of the 1,937 trials are tagged with Crohn Disease itself; the rest are tagged with a narrower condition beneath it.

Get the Crohn Disease report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Crohn Disease trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 118

1990: 1 trials (Observational 1) 1995: 3 trials (Observational 1, Not applicable 1, Phase 2/3 1) 1996: 3 trials (Observational 1, Phase 3 2) 1998: 1 trials (Observational 1) 1999: 2 trials (Observational 2) 2000: 7 trials (Observational 1, Not applicable 1, Phase 3 3, Phase 2 1, Phase 1 1) 2001: 9 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 2, Phase 1 2) 2002: 27 trials (Observational 5, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 12) 2003: 21 trials (Observational 7, Phase 4 1, Phase 3 7, Phase 2/3 1, Phase 2 4, Phase 1 1) 2004: 29 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 3 12, Phase 2 5, Phase 1/2 2, Phase 1 1) 2005: 34 trials (Observational 6, Not applicable 1, Phase 4 6, Phase 3 6, Phase 2/3 2, Phase 2 11, Phase 1/2 1, Phase 1 1) 2006: 44 trials (Observational 5, Not applicable 6, Phase 3 12, Phase 2 15, Phase 1/2 4, Phase 1 2) 2007: 46 trials (Observational 13, Not applicable 11, Phase 4 2, Phase 3 10, Phase 2/3 3, Phase 2 6, Phase 1/2 1) 2008: 44 trials (Observational 8, Not applicable 7, Phase 4 7, Phase 3 10, Phase 2/3 1, Phase 2 8, Phase 1/2 2, Phase 1 1) 2009: 42 trials (Observational 14, Not applicable 6, Phase 4 5, Phase 3 8, Phase 2/3 1, Phase 2 4, Phase 1/2 2, Phase 1 2) 2010: 58 trials (Observational 22, Not applicable 8, Phase 4 6, Phase 3 5, Phase 2 6, Phase 1/2 6, Phase 1 5) 2011: 73 trials (Observational 27, Not applicable 7, Phase 4 5, Phase 3 11, Phase 2/3 1, Phase 2 16, Phase 1/2 2, Phase 1 4) 2012: 72 trials (Observational 25, Not applicable 14, Phase 4 7, Phase 3 7, Phase 2 10, Phase 1/2 4, Phase 1 5) 2013: 65 trials (Observational 20, Not applicable 19, Phase 4 8, Phase 3 5, Phase 2 6, Phase 1/2 3, Phase 1 4) 2014: 88 trials (Observational 26, Not applicable 24, Phase 4 7, Phase 3 10, Phase 2/3 1, Phase 2 11, Phase 1/2 3, Phase 1 6) 2015: 99 trials (Observational 29, Not applicable 31, Phase 4 11, Phase 3 6, Phase 2 9, Phase 1/2 7, Phase 1 6) 2016: 79 trials (Observational 22, Not applicable 24, Phase 4 9, Phase 3 8, Phase 2/3 1, Phase 2 9, Phase 1/2 1, Phase 1 5) 2017: 96 trials (Observational 30, Not applicable 32, Phase 4 8, Phase 3 13, Phase 2/3 1, Phase 2 4, Phase 1/2 2, Phase 1 6) 2018: 98 trials (Observational 32, Not applicable 25, Phase 4 5, Phase 3 12, Phase 2/3 3, Phase 2 12, Phase 1 9) 2019: 101 trials (Observational 44, Not applicable 28, Phase 4 6, Phase 3 4, Phase 2/3 1, Phase 2 7, Phase 1/2 5, Phase 1 6) 2020: 101 trials (Observational 39, Not applicable 29, Phase 4 3, Phase 3 10, Phase 2/3 1, Phase 2 8, Phase 1/2 4, Phase 1 7) 2021: 117 trials (Observational 47, Not applicable 30, Phase 4 8, Phase 3 12, Phase 2/3 1, Phase 2 11, Phase 1/2 1, Phase 1 7) 2022: 116 trials (Observational 45, Not applicable 38, Phase 4 8, Phase 3 3, Phase 2/3 3, Phase 2 5, Phase 1/2 4, Phase 1 10) 2023: 98 trials (Observational 41, Not applicable 28, Phase 4 7, Phase 3 5, Phase 2/3 2, Phase 2 8, Phase 1/2 1, Phase 1 6) 2024: 118 trials (Observational 45, Not applicable 36, Phase 4 7, Phase 3 10, Phase 2/3 1, Phase 2 8, Phase 1/2 3, Phase 1 8) 2025: 112 trials (Observational 42, Not applicable 39, Phase 4 7, Phase 3 7, Phase 2/3 1, Phase 2 7, Phase 1/2 4, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 116
2025 112
2024 118
2023 98
2022 116
2021 117
2020 101
2019 101
2018 98
2017 96

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 130 trials starting in 2026 and about 120 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 184 trials still running at the 2026-10-09 snapshot; registered median of 29 months across 1,095 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Crohn Disease trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 119
Phase 1/2 66
Phase 2 220
Phase 2/3 27
Phase 3 211
Phase 4 149
Not applicable 487
Observational 652
Expanded access 6

How many Crohn Disease trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 90
Recruiting 291
Enrolling by invitation 19
Active, not recruiting 76
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Crohn Disease trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Takeda 68
AbbVie 46
Janssen Research & Development, LLC 25
Merck Sharp & Dohme LLC 15
UCB Pharma 15

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Crohn Disease? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
INFLIXIMAB 69
Certolizumab 30
Calcium-vitamin D3 10
Darvadstrocel 10
Calcium/Vitamin D 9

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Adalimumab-US 58
Ustekinumab SC 45
Vedolizumab IV 44
Azathioprine Pill 19
Risankizumab SC 17

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Crohn Disease trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Crohn's disease 2,582 106
CROHN'S DISEASE 1,567 27
Small intestinal obstruction 467 63
Crohn's Disease 399 26
Abdominal pain 350 69

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Crohn Disease? (2,167)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease. Journal of Crohn's & colitis 2026 Yes
Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2026 Yes
Combined [<sup>18</sup>F]-FDG PET-MR imaging for monitoring small bowel crohn's disease. European journal of nuclear medicine and molecular imaging 2026 Yes
Aberrant N-glycosylation may be a therapeutic target in carriers of a common and highly pleiotropic variant in the manganese transporter ZIP8. HGG advances 2026 Yes
Clinical Trial: Simplified Bowel Preparation for Small Bowel Capsule Endoscopy in Crohn's Disease. Alimentary pharmacology & therapeutics 2026 Yes

Showing 5 of 2,167 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages